---
title: "Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278208681.md"
description: "Lineage Cell Therapeutics, Inc. (LCTX) faces regulatory risks due to reliance on pluripotent cell lines that may not meet current donor eligibility standards. This could lead to special labeling, additional conditions, or limitations on use. If regulators find past donor screening inadequate, the company may need to conduct further studies or enhance controls, potentially impacting its business. The average stock price target for LCTX is $9.00, suggesting a 386.49% upside potential."
datetime: "2026-03-07T06:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278208681.md)
  - [en](https://longbridge.com/en/news/278208681.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278208681.md)
---

# Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges

Lineage Cell Therapeutics, Inc. (LCTX) has disclosed a new risk, in the Supply Chain category.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Lineage Cell Therapeutics, Inc. faces added regulatory and commercialization risk because key programs rely on pluripotent cell lines that may be exempt from certain contemporary donor eligibility requirements, potentially triggering special labeling, added conditions, or use limitations. If regulators later deem historical donor screening or testing practices for these hES or iPSC lines insufficient, the company could be forced to perform additional studies, enhance manufacturing controls, or even halt affected programs, which would negatively impact its overall business and development prospects.

The average LCTX stock price target is $9.00, implying 386.49% upside potential.

To learn more about Lineage Cell Therapeutics, Inc.’s risk factors, click here.

### Related Stocks

- [LCTX.US](https://longbridge.com/en/quote/LCTX.US.md)

## Related News & Research

- [Lineage Therap Expands ATM Equity Offering Capacity](https://longbridge.com/en/news/278736148.md)
- [B. Riley Financial Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price](https://longbridge.com/en/news/280499799.md)
- [US Economy Stays Resilient, But 'Significant Risks' Are Building Fast, Jamie Dimon Warns](https://longbridge.com/en/news/282712767.md)
- [IonQ stock soars on two announcements: valuation risks remain?](https://longbridge.com/en/news/282722275.md)
- [10:57 ETMiracell Receives FDA 510(k) Clearance for SMART M-CELL PRP Concentration System and SMART M-CELL Bone Marrow Concentration System](https://longbridge.com/en/news/282363343.md)